Hepatitis News : Hep C Protease Inhibitor Incivek Is Safe, Effective for HIV Coinfection
A Smart + Strong Site
Subscribe to:
Hep Magazine In Bulk
Hep Newsletter
Join Us:

Back to home » Hepatitis News » November 2012


November 15, 2012

Hep C Protease Inhibitor Incivek Is Safe, Effective for HIV Coinfection

People living with both HIV and the hepatitis C virus (HCV) experience high hepatitis cure rates from an Incivek (telaprevir)–based triple combination therapy, compared with those taking interferon and ribavirin alone, aidsmap reports. Vertex Pharmaceuticals presented the results of its Phase II trial at the annual meeting of the American Association for the Study of Liver Diseases (AALSD) in Boston. The findings echoed and re-affirmed previous results announced at the 2012 Conference on Retroviruses and Opportunistic Infections in March.

The randomized controlled trial examined the effects of Incivek along with pegylated interferon and ribavirin among HCV treatment-naive coinfected people with HCV genotype-1, the most common strain and the most difficult to treat. Divided into two arms, the study examined 13 participants with CD4 counts above 500 who had not yet taken antiretrovirals (ARVs) for HIV, as well as 47 patients on ARVs with a stable viral load. All participants randomly received either Incivek or a placebo along with pegylated interferon and ribavirin for 12 weeks, followed by another 36 weeks of just the peg-interferon plus ribavirin combination.

Across the board, 74 percent of those taking Incivek triple combination therapy maintained a sustained virological response (SVR, considered a cure) 24 weeks after finishing treatment, while only 45 percent of the control group achieved the same. Those not taking antiretrovirals experienced respective SVR rates of 71 and 33 percent. Side effects were elevated among those taking Incivek, with the most notable increased including itching, headache, nausea, skin rash and dizziness. However, the overall safety and tolerability profile of the triple combination therapy proved comparable to previous studies of people living with only hepatitis C.

To read the aidsmap article, click here.

Search: Hepatitis C, HCV, virus, HIV, cure, Incivek, telaprevir, triple combination therapy, Vertex Pharmaceuticals, American Association for the Study of Liver Diseases, AASLD, Conference on Retroviruses and Opportunistic Infections, CROI, pegylated interferon, ribavirin, treatment-naive, sustained virologic response, SVR, safety, tolerability

Scroll down to comment on this story. Click here to visit the Hep Forums and ask questions about this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The Hep team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (2 total)

[Go to top]

Quick Links
Current Issue
Hep TV
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis C
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
Tell us what you think
Should Medicaid limit access to new hep C drugs?

Hepatitis C Reader Survey
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.